Clinical Trial Activity: Rare Cancers and Rare Diseases and Unmet Needs
The Australian Government is investing in clinical trials to improve treatments and discover cures for debilitating and deadly rare cancers, rare diseases and areas of unmet need.
What we’re funding
To date the Australian Government has invested $75 million to stimulate clinical trial and registry activity. Research into rare cancers and rare diseases are getting priority funding.
You can view a list of grant recipients for this initiative within the overall Medical Research Future Fund (MRFF) grant recipients document.
The purpose of this research funding is to:
- increase clinical trial activity in Australia and develop new drugs, devices and treatments
- increase opportunities for patients involved in clinical trials and benefiting from the latest research
- reaffirm Australia’s position as a preferred destination for clinical trials.
This competitive grant program will target clinical trials and registries that will address areas of disease burden and unmet need.
Why it’s important
- Clinical trials guide the development of new drugs, devices, therapies and models of care.
- An increased focus is needed on under researched health priorities and conditions, such as rare cancers and rare diseases.
- Rare cancers with low survival rates together accounted for 47% of all cancer deaths in 2014.
- While survival rates for high incidence cancers have improved, those for rare cancers have remained relatively static.
- People living with a rare disease face significant challenges including diagnostic delays, lack of available treatments and difficulty in finding the appropriate care.
How to apply
Applications for this program are closed. You may wish to register on GrantConnect website to ensure you are alerted to all grant opportunities.